The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells

Ibrutinib blocks B-cell receptor signaling and interferes with leukemic cell-to-microenvironment interactions. Ibrutinib plays a key role in the management of B-CLL and is recommended for first line treatment of high-risk CLL patients with 17p deletion. Therefore, elucidating the factors governing s...

Descripción completa

Detalles Bibliográficos
Autores principales: Secchiero, Paola, Voltan, Rebecca, Rimondi, Erika, Melloni, Elisabetta, Athanasakis, Emmanouil, Tisato, Veronica, Gallo, Stefania, Rigolin, Gian Matteo, Zauli, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601728/
https://www.ncbi.nlm.nih.gov/pubmed/28938632
http://dx.doi.org/10.18632/oncotarget.19494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601728/
https://www.ncbi.nlm.nih.gov/pubmed/28938632
http://dx.doi.org/10.18632/oncotarget.19494

Ejemplares similares